BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 7170838)

  • 1. The spontaneously hyperlipidemic old rat as a model for evaluation of hypolipoproteinemic drugs. Effects of nicotinic acid, clofibrate and ethyl 2-(4-dibenzofuranyloxy)-2-methylpropionate on plasma lipoproteins.
    Gustafsson K; Kiessling H
    Z Versuchstierkd; 1982; 24(5-6):262-70. PubMed ID: 7170838
    [No Abstract]   [Full Text] [Related]  

  • 2. The mouse as a model for evaluation of hypotriglyceridemic drugs effects of nicotinic acid, clofibrate and ethyl 2-(4-dibenzofuranyloxy)-2-methylpropionate on plasma lipoproteins.
    Gustafsson K; Kiessling H
    Z Versuchstierkd; 1982; 24(5-6):271-7. PubMed ID: 7170839
    [No Abstract]   [Full Text] [Related]  

  • 3. Potential hypolipidemic agents. XVII. Synthesis and plasma lipid-lowering properties of compounds related to ethyl 2-(4-dibenzofuranyloxy)-2-methylpropionate and ethyl 2-(4-chlorophenoxy)-2-methylpropionate.
    Högberg T; Bondesson G; Stjernström NE
    Acta Pharm Suec; 1977; 14(2):149-60. PubMed ID: 906832
    [No Abstract]   [Full Text] [Related]  

  • 4. Potential hypolipidemic agents. XIV. Synthesis and plasma lipid-lowering properties of substituted biphenyls, diphenyl ethers and benzofurans related to ethyl 2-(4-dibenzofuranyloxy)-2-methylpropionate.
    Bondesson G; Högberg T; Misiorny A; Stjernström NE
    Acta Pharm Suec; 1976; 13(2):97-106. PubMed ID: 937013
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of bezafibrate on serum lipids in normo- and spontaneously hyperlipidemic rats.
    Pill J; Wolff S; Stegmeier K; Schmidt FH
    Methods Find Exp Clin Pharmacol; 1988 Aug; 10(8):487-92. PubMed ID: 3226219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effects of methy-2[(chloro-4'-benzoyl)-4-phenoxy]-2 propionic acid on the respiratory activity of isolated rat liver mitochondria].
    De Grimal P; Goudonnet H; Truchot R
    C R Seances Soc Biol Fil; 1977; 171(1):93-9. PubMed ID: 143334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of ethofibrate [2-(nicotinoyloxy)ethyl-p-chlorophenoxyisobutyrate] on lipid metabolism. I. Effect on blood lipids in normal and hyperlipemic rats].
    Maroto ML; Priego JG; Piña M; Catalán RE
    Arch Farmacol Toxicol; 1978 Apr; 4(1):25-7. PubMed ID: 697396
    [No Abstract]   [Full Text] [Related]  

  • 8. [Effect of short-term use of clofibrate on the blood level of cholesterol, beta lipoproteins and free fatty acids].
    Modzelewski A; Zaczek-Modzelewska T
    Wiad Lek; 1970 Nov; 23(21):1937-9. PubMed ID: 5485649
    [No Abstract]   [Full Text] [Related]  

  • 9. Hypolipemic activity of clofibrate-related compounds.
    Metz G; Specker M
    Arzneimittelforschung; 1975 Nov; 25(11):1686-92. PubMed ID: 1243074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [On the effect of etofylline clofibrate on serum lipids and lipoproteins in patients with hyperlipoproteinemia of various degrees (author's transl)].
    Schneider J; Mühlfellner G; Mühlfellner O; Hausmann L; Schubotz R
    Arzneimittelforschung; 1980; 30(11b):2059-62. PubMed ID: 7194060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the hypolipaemic activity of etofylline clofibrate, a new ester of etofylline and clofibric acid, and comparison with effects of known hypolipaemic agents.
    Davies JE; Kellett DN
    Arzneimittelforschung; 1980; 30(11b):2035-7. PubMed ID: 7194055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studies on serum lipoproteins of rats developing spontaneous hyperlipidemia.
    Gustafsson K; Kiessling H
    Artery; 1981; 9(6):456-76. PubMed ID: 7337554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical and therapeutic evaluation of a new antilipemic substance].
    de Aguiar Magano L
    Arch Sci Med (Torino); 1980; 137(1):131-9. PubMed ID: 7458646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypolipaemic activity of 1-(theophyllin-7-yl)-ethyl-2-[2-(p-chlorophenoxy)-2-methylpropionate] (etofylline clofibrate) and its analogues in normolipaemic rats.
    Ginocchio AV; Metz G
    Arzneimittelforschung; 1980; 30(11b):2032-4. PubMed ID: 7194054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Lipid depression by etofibrate in a comparative study in rats with artificial hyperlipidemia].
    Sterner W; Schultz A
    Arzneimittelforschung; 1974 Dec; 24(12):1990-2. PubMed ID: 4480360
    [No Abstract]   [Full Text] [Related]  

  • 16. [Arteriosclerosis--nicotinic acid therapy. 2. Alterations in serum lipoproteins. Diagnosis, therapy].
    Gustafson A
    Lakartidningen; 1971 Apr; 68(15):1744-5 passim. PubMed ID: 5577244
    [No Abstract]   [Full Text] [Related]  

  • 17. Differential effects of benzodioxane, chroman and dihydrobenzofuran analogs of clofibrate in a Triton hyperlipemic rat model.
    Newman HA; Heilman WP; Witiak DT
    Lipids; 1973 Jul; 8(7):378-84. PubMed ID: 4724016
    [No Abstract]   [Full Text] [Related]  

  • 18. Design, synthesis and hypolipidemic activity of novel 2-(naphthalen-2-yloxy)propionic acid derivatives as desmethyl fibrate analogs.
    Idrees GA; Aly OM; Abuo-Rahma Gel-D; Radwan MF
    Eur J Med Chem; 2009 Oct; 44(10):3973-80. PubMed ID: 19450906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Problems of long-term treatment of hyperlipoproteinemia with clofibrinic acid].
    Hanefeld M; Schulze J; Fritz T; Kemmer C
    Z Gesamte Inn Med; 1973 May; 28(10):Suppl 10:160 c. PubMed ID: 4200340
    [No Abstract]   [Full Text] [Related]  

  • 20. Human plasma fatty acid composition: the features of hyperlipoproteinemia and the influence of -linolenate and clofibrate.
    Takayasu K; Tada T; Okada F; Yoshikawa I
    Jpn Circ J; 1971 Sep; 35(9):1059-69. PubMed ID: 5172104
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.